Search research articles
Contact Us
Filters
Showing results (41-50 of 52) with videos related to
Page
of 6
Sort By:
Frontiers in Immunology
|
January 30, 2023
Robust humoral and cellular recall responses to AZD1222 attenuate breakthrough SARS-CoV-2 infection compared to unvaccinated
Jill Maaske, Stephanie Sproule, Ann R Falsey, et al.
Eclinicalmedicine
|
December 6, 2021
A phase 2/3, participant-blind, observer-blind, randomised, controlled study to assess the safety and immunogenicity of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine) in adults in India
Prasad S Kulkarni, Chandrasekaran Padmapriyadarsini, Johan Vekemans, et al.
Mayo Clinic Proceedings. Innovations, Quality & Outcomes
|
July 21, 2025
Immunogenicity and Safety of ChAdOx1 nCoV-19 (AZD1222) as a Homologous Fourth-Dose Booster: A Substudy of the Phase 3 COV003 Trial in Brazil
Sue Ann Costa Clemens, Sagida Bibi, Natalie G Marchevsky, et al.
Human Vaccines & Immunotherapeutics
|
March 21, 2024
Seropersistence of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine): 6-month follow-up of a randomized, controlled, observer-blind, phase 2/3 immuno-bridging study in Indian adults
Prasad S Kulkarni, Chandrasekaran Padmapriyadarsini, Johan Vekemans, et al.
NPJ Vaccines
|
April 18, 2026
Correlates of severe and delta COVID-19 in a phase 3 trial of the AZD1222 vaccine
Holly Janes, Youyi Fong, Ying Huang, et al.
Science Translational Medicine
|
January 25, 2022
The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans
Yueh-Ming Loo, Patrick M McTamney, Rosalinda H Arends, et al.
Nature Communications
|
April 10, 2024
The genomic evolutionary dynamics and global circulation patterns of respiratory syncytial virus
Annefleur C Langedijk, Bram Vrancken, Robert Jan Lebbink, et al.
The Lancet. Infectious Diseases
|
March 20, 2023
Nirsevimab binding-site conservation in respiratory syncytial virus fusion glycoprotein worldwide between 1956 and 2021: an analysis of observational study sequencing data
Deidre Wilkins, Annefleur C Langedijk, Robert Jan Lebbink, et al.
NPJ Vaccines
|
March 10, 2023
Immune correlates analysis of a phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine
David Benkeser, Youyi Fong, Holly E Janes, et al.
The New England Journal of Medicine
|
September 29, 2021
Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine
Ann R Falsey, Magdalena E Sobieszczyk, Ian Hirsch, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 52) with videos related to
Sort By:
Page
of 6
Frontiers in Immunology
|
January 30, 2023
Robust humoral and cellular recall responses to AZD1222 attenuate breakthrough SARS-CoV-2 infection compared to unvaccinated
Jill Maaske, Stephanie Sproule, Ann R Falsey, et al.
Eclinicalmedicine
|
December 6, 2021
A phase 2/3, participant-blind, observer-blind, randomised, controlled study to assess the safety and immunogenicity of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine) in adults in India
Prasad S Kulkarni, Chandrasekaran Padmapriyadarsini, Johan Vekemans, et al.
Mayo Clinic Proceedings. Innovations, Quality & Outcomes
|
July 21, 2025
Immunogenicity and Safety of ChAdOx1 nCoV-19 (AZD1222) as a Homologous Fourth-Dose Booster: A Substudy of the Phase 3 COV003 Trial in Brazil
Sue Ann Costa Clemens, Sagida Bibi, Natalie G Marchevsky, et al.
Human Vaccines & Immunotherapeutics
|
March 21, 2024
Seropersistence of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine): 6-month follow-up of a randomized, controlled, observer-blind, phase 2/3 immuno-bridging study in Indian adults
Prasad S Kulkarni, Chandrasekaran Padmapriyadarsini, Johan Vekemans, et al.
NPJ Vaccines
|
April 18, 2026
Correlates of severe and delta COVID-19 in a phase 3 trial of the AZD1222 vaccine
Holly Janes, Youyi Fong, Ying Huang, et al.
Science Translational Medicine
|
January 25, 2022
The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans
Yueh-Ming Loo, Patrick M McTamney, Rosalinda H Arends, et al.
Nature Communications
|
April 10, 2024
The genomic evolutionary dynamics and global circulation patterns of respiratory syncytial virus
Annefleur C Langedijk, Bram Vrancken, Robert Jan Lebbink, et al.
The Lancet. Infectious Diseases
|
March 20, 2023
Nirsevimab binding-site conservation in respiratory syncytial virus fusion glycoprotein worldwide between 1956 and 2021: an analysis of observational study sequencing data
Deidre Wilkins, Annefleur C Langedijk, Robert Jan Lebbink, et al.
NPJ Vaccines
|
March 10, 2023
Immune correlates analysis of a phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine
David Benkeser, Youyi Fong, Holly E Janes, et al.
The New England Journal of Medicine
|
September 29, 2021
Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine
Ann R Falsey, Magdalena E Sobieszczyk, Ian Hirsch, et al.
Page
of 6